ARBs	Angiotensin II receptor blockers
BRPC	Borderline resectable pancreatic cancer
CA19-9	Carbohydrate antigen 19-9
CAR T	Chimeric antigen receptor T
CXC	Chemokine
CDF	Difluorinated-curcumin
CDKN	Cyclin-dependent kinase inhibitor
CRP	C-reactive protein
CSF1R	Colony stimulating factor 1 receptor
CT	Computed tomography;
CTGF	Connective tissue growth factor
CTLA4	Cytotoxic T-lymphocyte-associated protein 4
DIM	3,3′-diindolylmethane
DDL4	Delta like canonical notch ligand 4
ECE1	Endothelin converting enzyme 1
ECF	Extracellular matrix
EGF	Epidermal growth factor
FAK	Focal adhesion kinase
FDA	Food and Drug Administration
FLT3	Tyrosine-protein kinase
Gy	Gray
HA	Hyaluronic acid
hENT	Human equilibrative nucleoside transporter
IGF1R	Insulin-like growth factor 1 receptor
JAK	Janus kinase
LAPC	Locally advanced pancreatic cancer
LN	Lymph-node ratio
LV	Leucovorin
MAGE-A3	Melanoma-associated antigen 3
MAPK	Mitogen-activated protein kinase
MLH1	MutL homolog 1
neoCRT	Neoadjuvant chemoradiotherapy
OS	Overall survival
PanIN	Pancreatic intraepithelial neoplasia
PARP	Poly ADP ribose polymerase
PD	Pancreaticoduodenectomy
PDAC	Pancreatic ductal adenocarcinoma
PDGFR	Platelet-derived growth factor receptor
PD-L1	Programmed death-ligand 1
PFS	Progression free survival
PS	Performance status
PSCs	Pancreatic stellate cells
PV	Portal vein
RT	Radiotherapy
SMAD4	Mothers against decapentaplegic homolog 4
SMV	Superior mesenteric vein
SOCS1	Suppressor of cytokine signalling 1
PUMA	p53 upregulated modulator of apoptosis
TK	Tyrosine kinase
TNM	Tumour node metastasis
VEGFR	Vascular endothelial growth factor receptor